Biomedical patents. Broad patent faces narrow odds in court battle.
Ken
K
Garber
D001709:Biotechnology / Q000331:legislation & jurisprudence*; D004345:Drug Industry / Q000331:legislation & jurisprudence*; D007603:Jurisprudence; D016328:NF-kappa B / Q000037:antagonists & inhibitors* / Q000502:physiology*; D010330:Patents as Topic; D011486:Protein C / Q000494:pharmacology / Q000627:therapeutic use; D020849:Raloxifene Hydrochloride / Q000494:pharmacology / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D014481:United States
D016328:NF-kappa B; D011486:Protein C; D011994:Recombinant Proteins; D020849:Raloxifene Hydrochloride; C421124:drotrecogin alfa activated